(Q35105390)

6 August 2017

1 reference

title

Fluconazole: optimized antifungal therapy based on pharmacokinetics (English)

1 reference

6 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1111/J.1439-0507.2002.TB04768.X

23 December 2023

1 reference

G. Silling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12690970

23 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12690970

23 December 2023

publication date

1 January 2002

1 reference

full work available at URL

6 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1439-0507.2002.tb04768.x

1 reference

https://api.crossref.org/works/10.1111/J.1439-0507.2002.TB04768.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1439-0507.2002.tb04768.x

23 December 2023

1 reference

https://api.crossref.org/works/10.1111/J.1439-0507.2002.TB04768.X

23 December 2023

1 reference

6 August 2017

volume

45 Suppl 3

1 reference

6 August 2017

page(s)

39-41

1 reference

Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Fungal infection in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Clinical pharmacokinetics of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

High-dose therapy with fluconazole > or = 800 mg day-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Is there a correlation between serum antifungal drug concentration and clinical outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2002.TB04768.X

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome

21 January 2018

series ordinal

6

1 reference

https://api.crossref.org/works/10.1111/J.1439-0507.2002.TB04768.X

Treatment of Candida albicans fungaemia with fluconazole

23 December 2023

series ordinal

11

1 reference

https://api.crossref.org/works/10.1111/J.1439-0507.2002.TB04768.X

23 December 2023

Identifiers

1 reference

6 August 2017

1 reference